The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis
| Autor: | Jing Huang, Que Zhu, Yuanqing Yao, Bo Xiong, Shunkang Rong, Gang Yang, Yun Du, Yonghong Jiang, Dan Nie, Jun Qian |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cardiac function curve
medicine.medical_specialty Myocardial Infarction Heart failure Acute myocardial infarction law.invention Angiotensin Receptor Antagonists Randomized controlled trial law Internal medicine medicine Diseases of the circulatory (Cardiovascular) system Humans Myocardial infarction cardiovascular diseases Ejection fraction business.industry Aminobutyrates Biphenyl Compounds Stroke Volume Sacubitril–valsartan Original Articles medicine.disease Angiotensin receptor blockers Confidence interval RC666-701 Relative risk Cardiology Meta‐analysis Valsartan Original Article Cardiology and Cardiovascular Medicine business Sacubitril Valsartan Angiotensin‐converting enzyme inhibitors |
| Zdroj: | ESC Heart Failure ESC Heart Failure, Vol 8, Iss 6, Pp 4852-4862 (2021) |
| ISSN: | 2055-5822 |
| Popis: | Aims We aimed to investigate whether sacubitril–valsartan could further improve the prognosis, cardiac function, and left ventricular (LV) remodelling in patients following acute myocardial infarction (AMI). Methods and results We searched the PubMed, Embase, Cochrane Library, and China National Knowledge Infrastructure (CNKI) from inception to 10 May 2021 to identify potential articles. Randomized controlled trials (RCTs) meeting the inclusion criteria were included and analysed. Thirteen RCTs, covering 1358 patients, were analysed. Compared with angiotensin‐converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB), sacubitril–valsartan did not significantly reduced the cardiovascular mortality [risk ratio (RR) 0.65, 95% confidence interval (CI) 0.22 to 1.93, P = 0.434] and the rate of myocardial reinfarction (RR 0.65, 95% CI 0.29 to 1.46, P = 0.295) of patients following AMI, but the rate of hospitalization for heart failure (HF) (RR 0.48, 95% CI 0.35 to 0.66, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text